Larson Financial Group
LXRX icon

Larson Financial Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Larson Financial Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-100
Closed -$240 – 3956
2026
Q2 		$240 Hold
100
– – ﹤0.01% 3581
2026
Q1 		$156 Hold
100
– – ﹤0.01% 3480
2025
Q4 		$115 Hold
100
– – ﹤0.01% 3325
2025
Q3 		$135 Hold
100
– – ﹤0.01% 3296
2025
Q2 		$95 Hold
100
– – ﹤0.01% 3169
2025
Q1 		$46 Hold
100
– – ﹤0.01% 2994
2024
Q4 		$74 Hold
100
– – ﹤0.01% 2655
2024
Q3 		$157 Hold
100
– – ﹤0.01% 2439
2024
Q2 		$168 Buy
+100
New +$179 ﹤0.01% 2120

Other funds holding LXRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Compagnie Lombard Odier SCmA
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.8B AUM 25.65% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Scheeler Financial
Scheeler Financial West Chester, Ohio $132M AUM

Larson Financial Group's LXRX Position: Q3 2026 in Review

Larson Financial Group sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2026, closing a stake of 100 shares — an estimated $240 sold.

Larson Financial Group first reported a position in LXRX in Q2 2024 and held it in 9 quarters. The position peaked at $240 in Q2 2026. 66 funds tracked by Wall St. Rank hold LXRX as of Q3 2026.

  • Larson Financial Group reported no remaining Lexicon Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Larson Financial Group sold 100 Lexicon Pharmaceuticals shares in Q3 2026, an estimated $240.
  • Larson Financial Group first reported a position in Lexicon Pharmaceuticals in Q2 2024 and held it in 9 quarters.
  • Larson Financial Group's Lexicon Pharmaceuticals position peaked at $240 in Q2 2026.
  • 66 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.